CJC-1295 + Ipamorelin

Two Receptors, One Somatotroph#

The whole reason this stack works better than either peptide alone is that CJC-1295 and ipamorelin hit different receptors on the same pituitary cell, and those receptors' signalling pathways amplify each other.

CJC-1295 (and its no-DAC sibling, Mod GRF 1-29) is a tetra-substituted analog of GHRH(1-29) — the bioactive fragment of endogenous growth-hormone-releasing hormone. It binds the GHRH receptor, a Gs-coupled GPCR on pituitary somatotrophs, elevates cAMP, and drives GH synthesis and release. The four amino acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) make the molecule resistant to DPP-IV and plasma proteases, so the GHRH signal actually survives long enough at the pituitary to matter.

Ipamorelin is a pentapeptide agonist at the growth hormone secretagogue receptor (GHS-R1a) — the same receptor ghrelin binds. Activation here amplifies GH release via the PLC/IP3/Ca²⁺ pathway and suppresses hypothalamic somatostatin tone, which is the "brake" on GH output.

"Dual agonism of GHRP and GHRH produces a synergistic effect, with co-administration substantially amplifying physiological GH pulse amplitude beyond the effect of either alone." — Ishida J. et al. JCSM Rapid Communications, 2020

Translation for the practical reader: running CJC with ipamorelin produces a GH pulse meaningfully larger than the sum of the two pulses you'd get from either peptide alone. That's why the community defaulted to this pairing.

Why Ipamorelin Won the GHRP Wars#

Older GHRPs — GHRP-2, GHRP-6, hexarelin — release GH effectively but drag cortisol, ACTH, and prolactin up with it. Elevated cortisol on-cycle is the last thing a physique-focused user wants, and GHRP-6's hunger response is unusable outside a bulk.

Ipamorelin was engineered around that problem. It's selective for the GH-releasing branch of GHS-R1a signalling and spares the HPA axis almost entirely.

"Ipamorelin selectively releases GH in both animals and humans without increasing ACTH, cortisol or prolactin, even at doses up to 200 times higher than the ED50 for GH release." — Raun K. et al. European Journal of Endocrinology, 1998

The practical payoff: you get a clean GH pulse, a mild hunger bump (nowhere near GHRP-6 territory), and no cortisol-driven water retention, fat gain, or sleep disruption. This is why ipamorelin is the default GHRP in bodybuilding and looksmaxxing protocols despite being weaker on paper than GHRP-2.

The DAC Mechanism: Why CJC-1295 Lasts for Days#

Standard GHRH has a half-life measured in minutes. Mod GRF 1-29 (no-DAC) stretches that to ~30 minutes. CJC-1295 with DAC does something architecturally different.

DAC stands for Drug Affinity Complex — a maleimidopropionic acid linker attached to the peptide. After injection, that linker forms a covalent bond with Cys34 of circulating serum albumin, producing a long-lived peptide-albumin bioconjugate that continues to activate GHRH receptors for days.

"CJC-1295 displayed prolonged receptor activation in vivo due to covalent binding to plasma proteins, resulting in long-lasting effects on GH secretion." — Jetté L. et al. Endocrinology, 2005

The pharmacokinetic consequence is dramatic:

"After multiple doses of CJC-1295, mean IGF-I levels remained above baseline for up to 28 days, and the half-life of CJC-1295 was 5.8–8.1 days in healthy adults." — Teichman SL. et al. Journal of Clinical Endocrinology & Metabolism, 2006

This is the core trade-off in the stack. DAC gives you tonic GHRH drive — fewer injections, steadier IGF-1, easier compliance. No-DAC (Mod GRF 1-29) gives you a sharp 30-minute pulse that resolves cleanly and mimics physiologic GHRH signalling. Users chasing recovery and IGF-1 elevation with minimal effort gravitate to DAC. Users who care about preserving pulse architecture — and most experienced peptide users do — stick with Mod GRF.

Pulsatility Is Preserved (Even With DAC)#

A reasonable concern with a week-long GHRH signal is that it flattens endogenous GH pulsatility — turning a normally pulsatile hormone into a tonic elevation, which in principle could downregulate receptors and dull the whole axis. The data says that doesn't happen to the degree you'd expect.

"Analysis indicated that endogenous GH pulse frequency and amplitude are preserved, rather than flattened, during continuous CJC-1295 stimulation." — Ionescu M, Frohman LA. Journal of Clinical Endocrinology & Metabolism, 2006

Hypothalamic somatostatin continues to impose its rhythmic brake on the somatotroph even when GHRH drive is elevated chronically. You get bigger pulses on the same underlying schedule, not a smeared-out flat line. This is a meaningful reason CJC-1295 remains viable long-term where older continuous-GHRH approaches struggled.

Downstream: GH → IGF-1 → The Effects You Actually Care About#

The pituitary GH pulse is the means, not the end. Released GH binds hepatic GH receptors and drives IGF-1 production, which is the primary mediator of the effects physique-focused users are chasing:

• Soft-tissue recovery and collagen synthesis — IGF-1 drives fibroblast proliferation, tendon remodelling, and skin collagen turnover. This is why CJC/Ipa stacks with BPC-157 for tendinopathy and why looksmaxxers report skin-quality changes at 8–12 weeks.
• Lipolysis — GH directly stimulates hormone-sensitive lipase in adipocytes, preferentially mobilizing visceral fat. The fat-loss effect is modest but real and skews toward the gut.
• Slow-wave sleep consolidation — nocturnal GH pulses are tightly coupled to deep sleep. A pre-bed CJC/Ipa pin amplifies the natural pulse window, which is why deeper sleep is the single most consistent user-reported effect in the first week.
• Lean-tissue quality — muscle fiber hypertrophy via IGF-1 is real but modest at peptide-driven GH levels. This stack is a tissue-quality and recovery amplifier, not an anabolic in the AAS sense.

Why This Is Not rHGH#

Worth stating plainly because the "CJC/Ipa vs HGH" question comes up constantly. Recombinant HGH delivers exogenous GH directly into circulation at a dose you pick — bypassing the pituitary entirely. CJC-1295 + ipamorelin can only ask your own somatotrophs to release more GH, and the pituitary has a ceiling. Above roughly 100 mcg of either peptide per injection, additional dose produces no additional GH release — the saturation dose concept that governs community dosing.

The consequence: CJC/Ipa produces a meaningful but bounded elevation in GH and IGF-1, preserves pulsatility, preserves negative feedback, and can't drive the supraphysiologic IGF-1 levels (and the gut growth, insulin resistance, and carpal tunnel) that 4–6 IU/day of rHGH will. That's a feature for most users and a limitation for competitive bodybuilders — which is exactly why the stack is the default entry point and rHGH is the tool of the serious end of the spectrum.

Common (most users)#

• Injection-site redness, itch, or small welts — usually histamine-mediated, worse with cold shots or under-reconstituted peptide. Rotate sites (lower abdomen, flanks, delts), let the vial warm in your hand for 30 seconds before pinning, and reconstitute with fresh bacteriostatic water.
• Flushing, tingling, or a brief head-rush in the first 5–15 minutes post-shot — classic GHRH effect from the CJC component. Fades within the first 1–2 weeks of consistent use. No action needed.
• Transient hunger spike — ipamorelin agonizes GHS-R1a (the ghrelin receptor), so some appetite bump is mechanistically expected. It's noticeably milder than GHRP-6 or GHRP-2. Time the pre-bed shot after your last meal, and run AM shots during a fasted window you were already planning to hold through.
• Water retention and mild puffiness — most visible in the face, hands, and ankles. Dose-dependent. If you look bloated rather than full, drop ipamorelin to 100 mcg per shot or cut one injection from the day.
• Numb or tingling hands / mild carpal-tunnel-like symptoms — classic GH fingerprint. Usually resolves on its own within 1–2 weeks; if it persists, that's an indication to reduce the dose.
• Vivid dreams and deeper sleep — most users experience this as a feature. Pre-bed dosing amplifies slow-wave sleep, which is exactly what you want.
• Morning grogginess after a pre-bed pin — usually transient. If it lingers past the first week, move the shot 30–60 minutes earlier or trim the ipamorelin dose.

Uncommon (dose-dependent or individual)#

• IGF-1 drift above the age-adjusted reference range — desirable up to the top of the range, problematic if you park significantly above it for months. Pull IGF-1 at baseline, again at week 8, then every 8–12 weeks. If you're well above range, drop a daily injection or cut the dose.
• Fasting glucose and HbA1c creep — GH is counter-regulatory to insulin, and the effect compounds over long runs. Check fasting glucose and HbA1c quarterly. If fasting glucose climbs above ~95–100 mg/dL or HbA1c trends up, reduce frequency (twice daily → once daily pre-bed) or take time off.
• Persistent edema or joint discomfort at higher doses — a sign you've pushed past your personal saturation. Return to 100 mcg Mod GRF + 100 mcg ipamorelin per shot; there's very little additional GH pulse above that anyway.
• Lipid shifts — usually mild but worth tracking if you're already running AAS. Include lipids on your standard cycle panel.
• Headaches — dose-dependent, often tied to water retention. Hydrate, drop the dose, reassess.

"Ipamorelin selectively releases GH in both animals and humans without increasing ACTH, cortisol or prolactin, even at doses up to 200 times higher than the ED50 for GH release." — Raun et al., Eur J Endocrinol (1998)

This is the single cleanest thing about ipamorelin relative to older GHRPs — no meaningful cortisol or prolactin noise, so you don't have to manage that on top of everything else.

Rare but serious#

• Worsening of proliferative retinopathy — GH/IGF-1 elevation can accelerate existing retinal neovascularization. New visual changes → stop immediately and get screened.
• Accelerated growth of occult malignancy — theoretical but mechanistically real; the GH/IGF-1 axis promotes cell proliferation. Unexplained weight loss, night sweats, or persistent localized pain are reasons to stop and get worked up.
• Symptomatic insulin resistance — polyuria, polydipsia, fatigue, blurred vision. Stop, check fasting glucose and HbA1c, and don't restart until metrics normalize.
• Severe injection-site reactions (spreading erythema, induration) — usually a contaminated or improperly stored vial. Discard and re-source.

Hard contraindications#

• Active or recently treated malignancy. GH and IGF-1 elevation promote proliferation across multiple tumor lines. Do not run CJC/ipa with any active cancer or during the post-treatment surveillance window — discuss reintroduction only after you're clearly in durable remission.
• Proliferative diabetic retinopathy. GH demonstrably worsens it.
• Uncontrolled type 2 diabetes. GH is counter-regulatory to insulin; running a GH secretagogue on top of already-impaired glucose control is the wrong direction.
• Pregnancy and lactation. Not studied. Do not run it.
• Known pituitary tumor / adenoma. A secretagogue is the last thing that pathology needs.

Gender, fertility, and PCT#

Both peptides are non-hormonal and do not touch the HPG axis — no testosterone suppression, no estrogen effects, no virilization risk. Women run the same doses as men (100 mcg Mod GRF + 100–200 mcg ipamorelin per shot) with the same response curve, and it's one of the few compounds on this site that genuinely is gender-neutral in dosing.

PCT is not required and not applicable. You can discontinue abruptly; endogenous GH pulsatility returns within days as the exogenous signal washes out.

"Analysis indicated that endogenous GH pulse frequency and amplitude are preserved, rather than flattened, during continuous CJC-1295 stimulation." — Ionescu & Frohman, JCEM (2006)

Pulsatility is preserved on CJC even with continuous exposure, which is part of why the side-effect profile stays cleaner than rHGH at equivalent IGF-1 elevations. Manage dose, pin fasted, track IGF-1 and glucose quarterly, and this is one of the lower-risk compounds in the physique-enhancement toolkit.